Levofloxacin is a member of the fluoroquinolone class of antibacterial agents.

See package insert for complete information.

LEVAQUIN is a fluoroquinolone antibacterial indicated in adults (≥18 years of age) with infections caused by designated, susceptible bacteria.

• Pneumonia: nosocomial and community acquired.
• Acute bacterialsinusitis.
• Acute bacterial exacerbation of chronic bronchitis.
• Skin and skin structure infections: complicated and uncomplicated.
• Chronic bacterial prostatitis.
• Urinary tract infections: complicated and uncomplicated.
• Acute pyelonephritis.
• Inhalational anthrax, post-exposure (1.13). Not tested in humans for post-exposure prevention of inhalational anthrax; plasma concentrations are likely to predict efficacy.

• Dosage in patients with normal renal function
• Adjust dose for creatinine clearance < 50 mL/min
• IV Injection, Single-Use or Premix: Slow IV infusion only, over 60 or 90 minutes depending on dose. Avoid rapid or bolus IV
• Dilute single-use vials to 5 mg/mL prior to IV infusion  
• Do not mix with other medications in vial or IV line

See package insert for complete information

The most common reactions (≥3%) were nausea, headache, diarrhea, insomnia, constipation and dizziness.

Known hypersensitivity to LEVAQUIN or other quinolones.

• Risk of tendinitis and tendon rupture is increased. This risk is further increased in older patients usually over 60 years of age, in patients taking corticosteroids, and in patients with kidney, heart or lung transplants. Discontinue if pain or inflammation in a tendon occurs.
• May exacerbate muscle weakness in persons with myasthenia gravis. Avoid use in patients with a known history of myasthenia gravis.
• Anaphylactic reactions and allergic skin reactions, serious, occasionally fatal, may occur after first dose.
• Hematologic (including agranulocytosis, thrombocytopenia), and renal toxicities may occur after multiple doses.
• Hepatotoxicity: Severe, and sometimes fatal, hepatoxicity has been reported. Discontinue immediately if signs and symptoms of hepatitis occur.
• Central nervous system effects, including convulsions, anxiety, confusion, depression, and insomnia may occur after the first dose. Use with caution in patients with known or suspected disorders that may predispose them to seizures or lower the seizure threshold.
• Clostridium difficile-associated colitis: evaluate if diarrhea occurs.
• Peripheral neuropathy: discontinue if symptoms occur in order to prevent irreversibility.
• Prolongation of the QT interval and isolated cases of torsade de pointes have been reported. Avoid use in patients with known prolongation, those with hypokalemia, and with other drugs that prolong the QT interval.